Trial Profile
A Retrospective, Descriptive, Three-Year Study Assessing the Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients Hospitalized for Acute Gastrointestinal Bleeding not Associated with Portal Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week.